Publication | Closed Access

LBP-20-VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial

ObesityMetabolic SyndromeHepatologyMedicineLiver PhysiologyHigh DosesPlacebo-controlled TrialLiver DiseaseThyroid HormonePhase 2MetabolismPharmacologyFatty Liver DiseaseHealth Sciences